As a founder, he has mapped the vision and strategy for the organization. He has experience in leveraging Asian competitiveness building successful global business in medical technology for GE and software for Wipro. As Exec Chairman of the Manipal Group, his focus was on developing a research thrust for the Group. Considered a thought leader in Health care and Life Sciences, he has worked in global leadership positions in GE and was Vice Chairman of Wipro. He serves on the board of various Pharma companies and Research institutes.
Prasanna is acknowledged in the healthcare sector as the pioneer in creating a market for high tech. medical equipment and delivering clinical excellence at low patient fees in Asian Hospitals, through innovative strategies. As the startup CEO of GE Medical in India, he also developed a $330 m Global Business in healthcare for GE Medical Systems (GEMS) by leveraging India's competitiveness taking the company from no 5 to No 1. He has also been a founding member of Wipro's team that initiated the company's entry into IT and was Vice Chairman of Wipro Ltd.
He is an independent Director of Take Solutions Ltd. He serves on the Governing Council of Center for Policy Research, India's leading Think Tank and of T A Pai Management Institute, a reputed Business School. He is a Trustee on Shriram Ownership Trust, which shapes the strategy of Shriram group of companies. He has served as Chairman of GEBEL, GEMS IT Ltd and GE X-Ray(South Asia) and Director of GE Yokogawa Medical Systems Ltd, Japan and GE Samsung Ltd, Korea, Wipro GE Medical Systems Ltd, India and Shasun Chemical & Drugs Ltd India. He brings rich experience in pharma and healthcare.
Mr. Prasanna is an alumnus of IIM Ahmedabad & GE Global Business Leadership Program at Crotonville.
Dr Ajay K Agrawal has extensive experience in the biotech & pharma industry worldwide. Dr Agrawal was a founder of polyMASC Pharmaceuticals plc, London, the first UK biotech company from a university that was directly listed on AIM, raising approximately $40 million in 1995, and subsequently merged with a NASDAQ-listed company, Valentis Inc, USA in 1999 to become one of the biggest companies in the delivery of biologics at that time. He has been the Managing Director of the Worldwide organization of collaborations in the pharmaceutical industry, London, and Director of business development of Lipoxen plc, AIM-listed company, in London.
Dr Agrawal has been an entrepreneur and advisor to the number of companies worldwide, and is currently a non-executive director, chairman of the remuneration and vice chairman of audit committees of ImmuPharma plc, AIM-listed company in London with operations in France and Switzerland, in the Board of Directors of Clinovo Ltd UK, Director of business development Almac Sciences UK, and a special advisor on healthcare for commonwealth British council, London.
Dr Agrawal currently sits on the editorial advisory board of four international pharmaceutical journals from the USA.
Lalit Mahapatra brings extensive experience in controllership, financial management and financial integration of business across services and geographies. He manages shareholders expectations and oversees corporate governance and leads the M&A activities of the company.
Prior to joining EA, Lalit worked with Schneider Electric Company as Head of Finance of the Global Technology Centre and the project contracting business. He was part of their global acquisition team and was instrumental in acquiring companies in India and Europe.
Lalit has over 15 years experience with companies like Siemens Information Processing Services Limited, Pacific Internet and Price Water House Cooper. His areas of expertise include strategic planning, fund management & harmonizing accounting practices to US GAAP, global IFRS standard and Indian GAAP. He is also a SAP champion in Finance module.
Lalit is a Chartered Accountant from the Institute of Chartered Accountants of India and a Certified Public Accountant from USA.